BioSpace News Archive

Agenus Inc. today announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high (MSS) or deficient mismatch repair (dMMR).

AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.

Portage Biotech Inc. today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.

TheracosBio today announced the publication of a study titled “Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus.

NeuroSense Therapeutics Ltd. announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School, will be presenting data from the PARADIGM Phase 2 study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting.

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced it has received approval of its divestment plan for GRAIL from the European Commission.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”) today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.

Eagle Pharmaceuticals, Inc. announced that it received a notice on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Biovica International Biovica, active in cancer monitoring, announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida.

Oncocyte Corporation, a precision diagnostics company, reported financial results for the year ended December 31, 2023.